Alunbrig scores NICE backing for ALK-positive lung cancer
ALK inhibitor recommended in the first-line non-small cell lung cancer setting
Read More
Tag: ALK mutations
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
